An Open-Label Drug-Drug Interaction Study in Healthy Male Subjects to Explore the Effects of Single and Multiple Doses of JNJ-39393406 on the Pharmacokinetics of a Single Oral Dose of Midazolam

Completed

• Conditions: alzheimer; psychose; 10057167; 10039628

• Registration Number: NL-OMON33240
• Lead Sponsor: Janssen-Cilag

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

Males
Between 18 and 55 years of age (inclusive)
BMI between 18 en 30 kg/m^2 (inclusive)

Exclusion Criteria

Clinical significant abnormalities for physical examination

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary purpose of this investigation is to examine the effect of single<br /><br>and multiple doses of the new drug JNJ-39393406 (the study medication) on<br /><br>absorption, metabolism and excretion by the body after single administration of<br /><br>the drug midazolam.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The other purpose of this investigation is to examine the safety and<br /><br>tolerability of the new drug JNJ-39393406 (the study medication).</p><br>